Tactile Systems Technology Inc. (NASDAQ: TCMD) has completed the acquisition of LymphaTech Inc. for $6.8 million in upfront payments, with additional compensation contingent upon achievement of specified milestones. The transaction strengthens Tactile Medical's existing lymphedema treatment portfolio by incorporating LymphaTech's proprietary 3D digital measurement platform, which enables clinicians to conduct more precise assessments of lymphatic dysfunction.
LymphaTech's measurement technology addresses a critical gap in lymphedema management by providing objective, three-dimensional imaging capabilities for disease identification and monitoring disease progression over time. The platform's integration into Tactile Medical's existing product suite—which includes compression therapy devices and related solutions—creates a more comprehensive diagnostic and treatment ecosystem for lymphatic disorders.
The acquisition underscores industry momentum in developing integrated care solutions for lymphedema, a chronic condition affecting lymphatic fluid circulation. By combining diagnostic capabilities with therapeutic devices, Tactile Medical positions itself to serve the full care continuum, potentially improving clinical outcomes while creating additional revenue streams through expanded service offerings.